Aimmune Therapeutics, Inc. (AIMT) Expected to Announce Earnings of -$0.72 Per Share

Analysts forecast that Aimmune Therapeutics, Inc. (NASDAQ:AIMT) will post earnings per share of ($0.72) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for Aimmune Therapeutics’ earnings, with estimates ranging from ($0.76) to ($0.69). Aimmune Therapeutics reported earnings of ($0.53) per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 35.8%. The firm is expected to report its next earnings report on Monday, November 13th.

According to Zacks, analysts expect that Aimmune Therapeutics will report full year earnings of ($2.57) per share for the current financial year, with EPS estimates ranging from ($2.72) to ($2.46). For the next financial year, analysts forecast that the business will post earnings of ($3.22) per share, with EPS estimates ranging from ($3.50) to ($3.05). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for Aimmune Therapeutics.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.01).

Several analysts have recently weighed in on AIMT shares. Piper Jaffray Companies set a $38.00 target price on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Saturday, October 21st. Zacks Investment Research lowered shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. Wedbush restated an “ourperform” rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a research report on Monday, August 14th. Credit Suisse Group boosted their price target on shares of Aimmune Therapeutics from $36.00 to $45.00 and gave the company an “outperform” rating in a research report on Monday, October 23rd. Finally, BidaskClub lowered shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $51.00.

Shares of Aimmune Therapeutics (NASDAQ AIMT) opened at $30.31 on Monday. Aimmune Therapeutics has a 12-month low of $15.97 and a 12-month high of $37.50.

ILLEGAL ACTIVITY NOTICE: “Aimmune Therapeutics, Inc. (AIMT) Expected to Announce Earnings of -$0.72 Per Share” was originally published by Week Herald and is the sole property of of Week Herald. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international copyright & trademark laws. The original version of this piece of content can be accessed at https://weekherald.com/2017/11/15/aimmune-therapeutics-inc-aimt-expected-to-announce-earnings-of-0-72-per-share.html.

In other news, insider Douglas T. Sheehy sold 47,425 shares of the company’s stock in a transaction that occurred on Monday, October 23rd. The shares were sold at an average price of $34.44, for a total transaction of $1,633,317.00. Following the transaction, the insider now directly owns 34,300 shares in the company, valued at $1,181,292. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Stephen George Dilly sold 4,047 shares of the company’s stock in a transaction that occurred on Friday, October 6th. The stock was sold at an average price of $26.31, for a total transaction of $106,476.57. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 315,815 shares of company stock worth $8,337,379. Company insiders own 17.59% of the company’s stock.

Several hedge funds have recently made changes to their positions in AIMT. Swiss National Bank lifted its position in shares of Aimmune Therapeutics by 17.5% during the first quarter. Swiss National Bank now owns 36,974 shares of the biotechnology company’s stock worth $803,000 after purchasing an additional 5,500 shares in the last quarter. American International Group Inc. lifted its position in shares of Aimmune Therapeutics by 7.1% during the first quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock worth $352,000 after purchasing an additional 1,070 shares in the last quarter. Teachers Advisors LLC lifted its position in shares of Aimmune Therapeutics by 2.6% during the first quarter. Teachers Advisors LLC now owns 44,349 shares of the biotechnology company’s stock worth $964,000 after purchasing an additional 1,120 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Aimmune Therapeutics by 30.5% during the first quarter. Vanguard Group Inc. now owns 2,199,858 shares of the biotechnology company’s stock worth $47,803,000 after purchasing an additional 513,803 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Aimmune Therapeutics by 5.3% during the first quarter. Geode Capital Management LLC now owns 207,210 shares of the biotechnology company’s stock worth $4,502,000 after purchasing an additional 10,461 shares in the last quarter. Institutional investors own 72.84% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get a free copy of the Zacks research report on Aimmune Therapeutics (AIMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply